An observational study in Alzheimer Disease and Mild Cognitive Impairment, sponsored by Weill Medical College of Cornell University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Weill Medical College of Cornell University · Observational
To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.
The Comparative Effectiveness Dementia \& Alzheimer's Registry (CEDAR) Project is a prospective, observational registry of adult patients at-risk for, or with, a diagnosis of dementia due to Alzheimer's disease (AD) or other neurodegenerative dementias. The purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of AD, or with memory loss or other changes in thinking. The registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to AD, and about the effectiveness of a clinical precision medicine intervention. Using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multidomain interventions on cognition, biomarkers of AD risk, and calculated AD risk across the pre-dementia spectrum of AD.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 452 is above the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Weill Medical College of Cornell University is the lead sponsor of 867 studies on the registry; 160 are open to participants now.
Of its 119 completed or terminated interventional studies of FDA-regulated products, 91 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male and female patients will be recruited at the Alzheimer's Prevention Clinic, Weill Cornell Medicine Memory Disorders Program.
Exclusion Criteria:
Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months
Composite Cognitive Battery (including NIH Toolbox Cognition Battery and other pen-and-paper neuropsychological tests).
Time frame: every 6 months, for 18 months
Change from Baseline in Cognitive Aging Composite (CAC) every 6 months
Composite Cognitive Battery, including neuropsychological tests related to non-pathological (age-related) cognitive decline.
Time frame: every 6 months, for 18 months
Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months
Measure longitudinal changes in a validated Alzheimer's risk scale (score range from -13 to 78) where higher scores confer higher risk
Time frame: 6 months
Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months
Measure longitudinal changes in a validated Alzheimer's risk scale (score range from 0 to 14) where higher scores confer higher risk
Time frame: 18 months
Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months
Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).
Time frame: 18 months
Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.
Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).
Time frame: 18 months
Change from Baseline in Cholesterol Biomarkers at 18 months
Change in blood serum levels of cholesterol (total, LDL, HDL) in mg/dL
Time frame: 18 months
Change from Baseline in Inflammatory Biomarkers at 18 months
Change in blood serum levels of hs-CRP, fibrinogen, Cystatin C in mg/dL
Time frame: 18 months
Change from Baseline in Metabolism Biomarkers at 18 months
Change in blood serum levels of HbA1c and HOMA-IR
Time frame: 18 months
Change from Baseline in Homocysteine at 18 months
Change in blood serum level of homocysteine
Time frame: 18 months
Change from Baseline in Vitamin D at 18 months
Change in blood serum level of Vitamin D
Time frame: 18 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University